Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Accumulated Expenses (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Accumulated Expenses readings, the most recent being $5.4 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 9.74% to $5.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Mar 2026, down 9.74% year-over-year, with the annual reading at $4.9 million for FY2025, 18.27% down from the prior year.
  • Accumulated Expenses hit $5.4 million in Q1 2026 for Ovid Therapeutics, up from $4.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8.1 million in Q2 2024 and bottomed at $2.2 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $5.1 million, with a median of $5.4 million recorded in 2026.
  • The largest annual shift saw Accumulated Expenses plummeted 83.51% in 2022 before it surged 87.74% in 2023.
  • Ovid Therapeutics' Accumulated Expenses stood at $4.5 million in 2022, then surged by 44.83% to $6.5 million in 2023, then decreased by 8.12% to $6.0 million in 2024, then dropped by 18.27% to $4.9 million in 2025, then rose by 10.49% to $5.4 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Accumulated Expenses are $5.4 million (Q1 2026), $4.9 million (Q4 2025), and $3.0 million (Q3 2025).